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 Abstract - Mast cell and basophils express the high 
affinity receptor for IgE (FcRI) and are primary 
effector cells of allergic disorders. The urokinase 
(uPA)-mediated plasminogen activation system is 
involved in physiological and pathological events 
based on cell migration and tissue remodelling, such 
as inflammation, wound healing, angiogenesis and 
metastasis. uPA is a serine protease that binds uPAR, 
a high affinity glycosyl-phosphatidyl-inositol (GPI)-
anchored receptor. uPAR focuses uPA activity at the 
cell surface and activates intracellular signaling 
through lateral interactions with integrins, receptor 
tyrosine kinases and the G-protein-coupled family of 
fMLF chemotaxis receptors (FPRs).  
We investigated the expression of the uPA-
uPAR system and its functional interaction with 
FPRs in human mast cells (MCs). Differently from 
basophils, MCs produced uPA that was able to 
induce their chemotaxis. Indeed, MCs also expressed 
uPAR, both in the intact and in a cleaved form (DII-
DIII-uPAR) that can expose, at the N-terminus, the 
SRSRY sequence, able to interact with FPRs and to 
mediate cell chemotaxis. MCs also expressed 
mRNAs for FPRs that were functionally active; 
indeed, uPA and a soluble peptide (uPAR84-95), 
containing the SRSRY chemotactic sequence of 
uPAR and able to interact with FPRs, were able to 
induce MCs chemotaxis.  
Thus, uPA is a potent chemoattractant for 
MCs acting through the exposure of the chemotactic 
epitope of uPAR, that is an endogenous ligand for 
FPRs. The same mechanism could be involved in 
VEGF-A secretion by human MCs, also induced by 
uPA and uPAR84-95 stimulation. 
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I.  INTRODUCTION 
 
 Mast cells (MCs) are haematopoietic cells widely 
distributed in vascularized tissues, at the interface with the 
external environment. Unlike other immune cells, MCs 
normally circulate through the vascular system as 
immature progenitors and undergo the terminal stages of 
their differentiation and/or maturation locally, after 
migration into vascularized tissues or serosal cavities, in a 
process regulated by multiple local factors [1]. The main 
factors that influence MCs number and phenotype include 
c-Kit ligand stem-cell factor (SCF) [2] and the chief 
survival and/or developmental factors for the MCs, IL-3 
and T helper type 2 (Th2)-associated cytokines such as IL-
4 and IL-9, but the complete list comprises a wide panel 
of other growth factors, cytokines and chemokines [1]. 
MCs abound especially near surfaces exposed to 
the environment, including the gastrointestinal and 
airways tract and skin, where pathogens, allergens and 
other environmental agents are frequently encountered [3-
5]. Due to their specific anatomical location, MCs have 
numerous functions; in particular they are responsible for 
the first line of defence against external pathogens and 
other environmental insults [6]. MCs are well known for 
their versatile role in allergic responses through the 
binding of specific antigens to the FcRI-IgE complex [1]. 
However, in recent years, it has been demonstrated that 
MCs contribute to a variety of non-allergic 
immunoregulatory reactions. MCs infiltrate the sites of 
chronic inflammation [7]; increased numbers of MCs have 
been found in the synovial tissues and fluids of patients 
with rheumatoid arthritis (RA), and at sites of cartilage 
erosion [8]. It has been reported that MC density is 
increased at the margins of various tumors in humans [9, 
10], modulating many aspects of the tumor natural history 
[11-13] and correlating with angiogenesis through the 
synthesis and release of a wide spectrum of angiogenic 
factors, such as Vascular Endothelial Growth Factor-A 
(VEGF-A) and Vascular Endothelial Growth Factor-B 
(VEGF-B), [14,15] and tumor invasion by releasing 
cytokines and proteases [12].  
The urokinase-type plasminogen activator 
receptor (uPAR, CD87) is a GPI-anchored protein that 
functions as the receptor for urokinase (uPA) [16]. uPAR, 
expressed by a wide variety of cells, including monocytes, 
macrophages, neutrophils and basophils [17,18], is formed 
by three homologous domains (DI, DII, DIII) [19]. The 
uPAR can be cleaved within the DI/DII linker region by 
several proteolytic enzymes, including uPA itself [20,21]. 
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The cleavage causes the release of DI from the molecule. 
Therefore, uPAR can exist on the cell surface in either a 
three-domain form (DI-DII-DIII-uPAR), which is capable 
of binding uPA, or a two-domain form (DII-DIII-uPAR), 
which does not bind uPA [20]. 
uPAR has important roles in both physiological 
and pathological processes; in addition to its regulatory 
role in fibrinolysis and inflammation, it has been 
implicated in tumor invasion, metastasis, fibrosis, and in 
the development of protective immunity in infections. In 
particular, uPAR is strongly up-regulated in several 
cancers where represents a negative prognostic factor 
[22]. uPAR traditional role was considered the focusing of 
proteolytic uPA activity on the cell membrane, however 
uPAR also binds vitronectin (VN), a component abundant 
in tumor-associated ECM [23], and interacts with various 
integrins regulating their activity. In addition uPAR 
mediates uPA-dependent cell migration and is required for 
chemotaxis induced by fMet-Leu-Phe (fMLF), a potent 
leukocyte chemoattractant. Through a specific site 
corresponding to amino acids 88-92 (SRSRY), located in 
the region linking uPAR domain 1 (DI) to uPAR domain 2 
(DII), the cell-surface uPAR functionally interacts with 
the N-formyl peptide receptors (FPRs) [24].  
FPRs are a family of pattern recognition 
receptors. It is now well known that, by interacting with 
several structurally diverse pro- and anti-inflammatory 
ligands, FPRs seem to possess important regulatory 
effects in multiple pathological conditions, including 
inflammation and cancer. FPRs are expressed in 
abundance on cells of the host defense system; in addition, 
all FPRs expressed on epithelia seem to be required for 
wound repair and restitution of barrier integrity, by 
facilitating epithelial cell migration, proliferation, and 
neo-angiogenesis [25]. Three variants of FPRs have been 
identified in humans: the high and low affinity receptors, 
FPR1 and FPR2, and the FPR3, which does not bind 
fMLF [26].  
Recently, new insight on the diversity of MC 
products, signalling mechanisms, and interactions with 
other cell types has led to many attractive hypotheses 
about the diverse potential effector and immunoregulatory 
roles of MCs in physiological and pathological conditions.  
In particular, several authors focused their attention on the 
role of MCs in tumor growth, starting from the 
observation that mast cell deficient mice show a reduced 
cancer infiltration [27]. Based on such evidences, in this 
study we investigated whether MCs, by expressing and 
modulating the FPRs and the uPA/uPAR system, could 




II.  METHODOLOGY 
 
Peptides and chemicals 
The following were purchased: di-isopropyl 
fluorophosphate (DFP; Fluka, Buchs, Switzerland); fMLF 
was from Calbiochem (La Jolla, CA); the peptide uPAR84–
95 was synthesized by PRIMM (Milan, Italy), the 59-(N-
ethylcarboxamido) adenosine (NECA) was from Sigma-
Aldrich (St. Louis, MO, USA), the phorbol myristate 
acetate (PMA) was obtained from LC Services (Woburn, 
MA), human uPA and the uPA N-terminal fragment 
(ATF) were from Sekisui Diagnostics (Lexington, MA, 
USA); PE-labeled anti-IgE Abs (Caltag Laboratories, 
Burlingame, CA); FITC-labeled goat anti-rabbit IgG 
(Abcam, Cambridge, U.K.). For chemotaxis assay 8-mm-
pore polycarbonate membranes (Nucleopore, Pleasanton, 
CA), TRIzol solution was from Invitrogen 
FischerScientific (Illkirch,France), and DNA ladder and 
Moloney leukemia virus reverse transcriptase were from 
Promega (Madison, WI). Protein concentration was 
estimated with a modified Bradford assay (Bio-Rad 
Laboratories). ECL Plus was from GE Healthcare 
(Buckinghamshire, UK). The mixture of protease and 
phosphatase inhibitors was from Calbiochem. Rabbit 
polyclonal anti-uPAR and monoclonal anti-uPA 
antibodies were from Sekisui Diagnostics, rabbit anti-actin 
was from Sigma-Aldrich (St. Louis, MO). Secondary anti-
mouse and anti-rabbit Abs coupled to HRP were from 
Bio-Rad (Munchen, Germany). RANTES was from 
PeproTech EC LTD (London, UK) and SCF was from 
recombinant human stem cell factor (SCF) from Amgen 
(Thousand Oaks, CA).  
 
Cell culture 
Human mast cell line HMC-1 was kindly donated 
by Dr. J.H. Butterfield (Mayo Clinic, Rochester, MN); 
cells were maintained in suspension culture at a density of 
3-9 x 105 cells/ml of IMDM supplemented with 10% FCS, 
2 mM L-glutamine, 1.2 mM monothioglicerol. 
The THP-1 monocyte-like cell line was grown in RPMI 
1640 medium supplemented with 10% heat-inactivated 
FCS [17,18].  
 
Isolation and purification of human lung mast cells 
(HLMC)  
 Lung tissue was obtained from patients 
undergoing thoracotomy and lung resection, after 
obtaining their informed consent according to the 
guidelines of the institutional review board. 
Macroscopically normal parenchyma was dissected free 
from pleura, bronchi, and blood vessels and minced into a 
single-cell suspension as previously described [28]. Yields 
ranged between 3x106 and 18x106 mast cells, and purity 
was between 1 and 8%. Lung mast cells were purified by 
countercurrent elutriation (J2/21; Beckman) and then by 
discontinuous Percoll density gradient as previously 
described. Mast cells were further purified to near 
homogeneity by positive selection: incubation with anti-
FcRI (IgG1) was followed by the exposure to magnetic 
beads coated with MACS goat anti-mouse IgG. Labeled 
cells were enriched by positive selection columns (MACS 
system; Miltenyi Biotec). The final preparations contained 
>95% viable cells, as assessed by the trypan blue 
exclusion method, and purity was  >98% mast cells. 
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RNA purification and analysis 
 Total cellular RNA was isolated by lysing cells in 
TRIzol solution, according to the supplier’s protocol [29]. 
RNA was precipitated and quantitated by spectroscopy. 
Five micrograms of total RNA was reversely transcribed 
with random hexamer primers and 200 U murine Moloney 
leukemia virus reverse transcriptase. One microliter of 
reverse-transcribed DNA was then amplified for FPR1, 
FPR2, FPR3, uPA, uPAR and GAPDH using specific 
primers. The primers for FPR1 were 5’-
ATGGAGACAAATTCCTCTCTC (sense) and 3’-
CACCTCTGCAGAAGGTAAAGT (antisense); for FPR2 
were 5’-CTTGTGATCTGGGTGGCTGGA (sense) and 
3’CATTGCCTGTAACTCAGTCTC (antisense); and for 
FPR3 were 5’AGTTGCTCCACAGGAATCCA (sense) 
and 3’-GCCAATATTGAAGTGGAGGATCAGA 
(antisense), for uPA were 5’-AAAATGCTATGTG 
CTGCTGACC (sense) and 3’CCCTGCCCTGAAG 
TCGTTAGTG (antisense) [24], for uPAR were 5’ 
CTGCGGTGCATGCAGTGT AAG (sense) and 
3’GGTCCAGAGGAGAGTGCCTCC (antisense) [18], for 
VEGF-A were 5’TCTTCAAGCCATCCTGTGTG (sense) 
and 3’GCCTCGGCTTGTCACATC (antisense) [30].  
 The primers for GAPDH were 5’GCCAAAGGG 
TCATCA TCTC (sense) and 3’-GTAGAGGCAGGGA 
TGATGTTC (antisense). PCR products, together with a 
DNA ladder as a size standard, were separated on a 1% 
agarose gel, stained with ethidium bromide, and quantified 
with the image analysis system ChemiDoc XRSn (Bio-
Rad Laboratories). 
 
Western blot  
 Immunoblotting experiments were performed 
according to standard procedures [31]. Briefly, cells were 
harvested in lysis buffer (50 mM HEPES, 150 mM NaCl, 
10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM 
MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, and 
1 mM Na3VO4) supplemented with a mixture of 
proteases and phosphatases inhibitors. The protein content 
was measured by a colorimetric assay. Fifty micrograms 
of protein was electrophoresed on a 10% SDS-PAGE 
under non reducing conditions and transferred onto a 
polyvinylidene fluoride membrane.   
 The membrane was blocked with 5% nonfat dry 
milk and probed with specific Abs: mouse anti-uPA 
(1g/ml), rabbit anti uPAR (1g/ml), and rabbit anti--
actin (0.5 g/ml). Finally, washed filters were incubated 
with HRP-conjugated anti-rabbit or antimouse Abs. The 
immunoreactive bands were detected by a 
chemiluminescence kit and quantified by densitometry 
(ChemiDoc XRS, BioRad). 
 
Flow cytometric analysis of surface molecules  
 Flow cytometric analysis of cell surface 
molecules was performed as previously described [18]. 
Briefly, after saturation of non specific binding sites with 
total rabbit IgG, cells were incubated for 20 min at +4°C 
with specific or isotype control antibodies. For indirect 
staining this step was followed by a second incubation for 
20 min at +4°C with an appropriate anti-isotype-
conjugated antibody. Finally, cells were washed and 
analyzed with a FACSCalibur Cytofluorometer using Cell 
Quest software (Becton & Dickinson, San Fernando, CA). 
A total of 104 events for each sample were acquired in all 
cytofluorimetric analyses. 
 
Chemotaxis assay  
Human lung mast cell (HLMC) chemotaxis was 
performed using a modified Boyden chamber technique as 
previously described [18]. Briefly, 25 µl of PACGM 
buffer or various concentrations of the chemoattractants in 
the same buffer were placed in triplicate in the lower 
compartment of a 48-well microchemotaxis chamber 
(Neuroprobe, Cabin John, MD). The lower compartments 
were covered with polycarbonate membranes with a two-
filter sandwich constituted by 5-µm (lower) and 8-µm 
(upper) pore size polycarbonate membranes (Nucleopore, 
Pleasanton, CA). Fifty microliters of the cell suspensions 
(5x104/well) resuspended in PACGM was pipetted into the 
upper compartments. The chemotactic chamber was then 
incubated for 3 h at 37°C in a humidified incubator with 
5% CO2 (automatic CO2 incubator, model 160 IR, 
ICN/Flow Laboratories). At the end of the incubation the 
upper polycarbonate filter was discarded, while the lower 
nitrate cellulose filter was fixed in methanol, stained with 
Alcian Blue, and then mounted on a microscope slide with 
Cytoseal (Stephen Scientific, Springfield, NJ).  
HLMC chemotaxis was quantitated 
microscopically by counting the number of cells attached 
to the surface of the 5-µm cellulose nitrate filter. In each 
experiment 10 fields/triplicate filter were measured at x 40 
magnification. The results were compared with buffer 
controls.  
Check board analysis was performed to 
discriminate between chemotaxis and nondirected 
migration (chemokines) of HLMC. In these experiments 
mast cells were placed in the upper chambers, and various 
concentrations of stimuli or buffer were added into the 
upper or lower wells or both. Spontaneous migration 
(chemokinesis) was determined in the absence of 
chemoattractant or when stimuli were added to both lower 
and upper chambers.  
The mast cell migratory responses to the stimuli 
were largely due to chemotaxis and not to chemokinesis. 
Indeed, a check board analysis, in which chemoattractants 
above and below the filters were varied, resulted in 
significant migration only when there was a gradient of 
the factor below the filters (data not shown). 
 
ELISA for VEGF-A 
VEGF-A content in cell lysates and in culture 
supernatants of human mast cells was measured in 
duplicate determinations with a commercially available 
ELISA (R&D Systems) [32]. 
 
Inactivation of uPA  
The uPA was inactivated by incubation with 10 
mM DFP for 2 h at 4°C [18].  
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III.  RESULTS 
 
Expression of uPAR and FPRs in the human mast cell line 
HMC-1 
In several conditions, such as in the fibroblast-to-
myofibroblast transition involved in the pathogenesis of 
inflammatory and neoplastic disorders, the uPA/uPAR 
system acts through the structural and functional 
interaction with FPRs [24].  
To investigate the existence of a functional 
interaction between the uPA-uPAR system and FPRs in 
MCs, we first evaluated the expression at mRNA and 
protein level of uPA and uPAR in HMC-1 cells. uPA and 
uPAR mRNAs were detected by RT-PCR analysis of 
RNAs from HMC-1 cells and THP-1 monocyte-like cells, 
used as a positive control (Fig. 1A).  
Western blot analysis of HMC-1 cell lysates with 
a monoclonal anti-uPA antibody confirmed the production 
of uPA. The same analysis with a polyclonal anti-uPAR 
antibody demonstrated that HMC-1 cells expressed uPAR 
in the intact (DI-DII-DIII-uPAR) and cleaved (DII-DIII-
uPAR) forms (Fig. 1B). This result was previously 
described in other cell types, including monocyte-like 
THP-1 cells [18]. 
DII-DIII-uPAR can interact with FPRs through 
its SRSRY chemotactic domain, exposed at the N-
terminus [21,33]. Moreover, upon binding uPA, intact 
uPAR can expose the same chemotactic domain, located 
in the DI-DII linker region, through a conformational 
modification [18]. Then, we examined FPRs expression in 
HMC-1 cells by RT-PCR analysis. Electrophoresis in 
agarose gel showed the presence of mRNAs for all three 
receptors: FPR1, FPR2 and FPR3 (Fig. 1C). 
These experiments demonstrated that MCs 
synthesized uPA and its specific receptor uPAR as well as 
FPRs, most important mediators of uPA/uPAR-induced 
cell responses in cancer and inflammation [16,22,24,31]. 
 
Effects of DFP-uPA and uPAR84-95 on VEGF-A expression 
and production in the HMC-1 human mast cell line  
It has been reported that human mast cells can 
express and synthesize VEGF-A and VEGF-B, as well as 
Vascular Endothelial Growth Factor-C (VEGF-C) and 
Vascular Endothelial Growth Factor-D (VEGF-D) [14, 
15].  
Thus, we evaluated whether uPA, both directly 
and/or by inducing uPAR interaction with FPRs, could 
stimulate VEGF-A expression and production by HMC-1 
cells.  
To this aim, HMC-1 cells were stimulated for 2 
hours with DFP inactivated-uPA (10-8 M), able to bind 
uPAR but devoid of enzymatic activity, and with the 
uPAR84-95 peptide (10-9 M), containing the SRSRY 
chemotactic sequence of uPAR and able to bind FPRs.  
RT-PCR analysis of VEGF-A mRNA expression 
showed that HMC-1 cells synthetized mRNA for VEGF-A 
after 2 hours stimulation with both ligands (Fig. 2A). 
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Figure 1. uPA, uPAR and FPRs expression in HMC-1 
cells. 
A: mRNA expression of uPA and uPAR in HMC-1 cells. Total 
RNA of THP-1 monocyte-like cells as a positive control (lane 1) 
and HMC-1 cells (lane 2) were prepared, reverse transcribed, 
and amplified by 40 PCR cycles in the presence of uPA and 
uPAR-specific primers and GAPDH primers, as a loading 
control. PCR products were analyzed by electrophoresis in 1% 
agarose gel containing ethidium bromide, followed by 
photography under UV illumination. 
B: Western blot analysis of uPA and uPAR in HMC-1 cells. 
THP-1 monocyte-like cells as a positive control (lane 1) and 
HMC-1 cells (lane 2) were lysed in Triton X-100 and 50 g of 
total protein were analyzed by 9% SDS-PAGE and Western blot 
with an anti-uPA and anti-uPAR polyclonal antibody. 
C: mRNA expression of FPRs in HMC-1 cells. Total RNA was 
prepared, reverse transcribed and amplified by 40 PCR cycles in 
the presence of FPR1- (lane 1), FPR2- (lane 2), and FPR3- (lane 
3) specific primers and GAPDH (lane 4) primers, as loading 
control. PCR products were analyzed by electrophoresis in 1% 
agarose gel containing ethidium bromide, followed by 
photography under UV illumination. 
 
To  evaluate  whether  DFP-uPA   and  uPAR84-95  
also induced VEGF-A production, we investigated the 
kinetics of VEGF-A release from HMC-1 cells. Both 
DFP-uPA and uPAR84-95 induced a time-dependent release 
of VEGF-A in HMC-1 cells (not shown) that was 
significant after 6 hours of stimulation (Fig 2B). 
 
Effect of DFP-uPA, and uPAR84–95 on primary human 
lung mast cells (HLMC) chemotaxis 
We demonstrated that uPA can induce human 
basophil chemotaxis through uPAR functional interaction 
with FPRs [18].  
Thus, we the studied uPAR expression and the 
existence of a functional interaction with FPRs also in 
primary human MCs. To this aim, human lung mast cells 
(HLMC) were purified from normal subjects and analyzed 
by flow cytometry with a polyclonal anti-uPAR antibody 
or with purified control IgG, then stained with FITC-
conjugated goat anti-rabbit IgG and PE-conjugated anti-
IgE. The vast majority (80–94%) of HLMC showed uPAR 
expression on the cell surface (Fig. 3A).  
In order to elucidate the potential interaction of 
cell-surface uPAR and FPRs, we tested the effects of 
DFP-inactivated uPA (10-9-10-8 M) and of different 
concentrations of the uPAR-derived chemotactic peptide 
uPAR84–95 (10-9-10-8 M) on purified HLMC chemotaxis. 
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Figure 2. Effect of ATF-uPA  and uPAR84-95 on VEGF-
A expression and release by HMC-1 cells. 
A: effect of ATF-uPA, uPAR84-95 on VEGF-A mRNA 
expression in HMC-1 cells. HMC-1 cells were cultured with cell 
medium alone, ATF-uPA (10-9 M), uPAR84-95 (10-10 M), or PMA 
(25 ng/ml), as a positive control, for 2 hours at 37°C in a 
humidified (5% CO2) incubator. Total RNA of HMC-1 cells was 
prepared, reverse transcribed and amplified by 40 PCR cycles in 
the presence of VEGF-A specific primers and GAPDH primers, 
as a loading control. PCR products were analyzed by 
electrophoresis in 1% agarose gel containing ethidium bromide, 
followed by photography under UV illumination. Results are 
expressed as percentage of VEGF-A expression increase in 10-9 
M ATF-uPA-treated (grey column), 10-10 M uPAR84-95-treated 
(light grey column), or 25 ng/ml PMA-treated (black column) 
HMC-1 cells,  relative to untreated HMC-1 cells (white column), 
after normalization to GAPDH. Values are the mean ± SEM of 
three experiments. * p:  <0.05. 
B: effect of ATF-uPA and uPAR84-95 on VEGF-A synthesis by 
HMC-1 cells. 106 cells/samples were incubated for 6 hours 
without (white column) or with ATF-uPA (10-9 M) (grey 
column), uPAR84-95 (10-10 M) (light grey column), or NECA (10-5 
M) (black column) at 37°C in a humidified (5% CO2) incubator. 
Results are expressed as percentage of increase of VEGF-A 
release relative to untreated cells. HMC-1 supernatants were 
collected and VEGF-A was determined by ELISA assay. Values 
are the mean ± SEM of three experiments. * p: <0.05. 
 
 
Both DFP-uPA and uPAR84-95 caused HLMC migration 
(Fig. 3B, C). Both the chemokine RANTES (10 and 100 
ng/ml) and the major chemotactic factor SCF (10 and 100 
ng/ml), used as a positive control, showed to be potent 
factors in HLMC migratory activity (Fig. 3B, C).  
To determine whether migration of HLMC 
resulted from chemotaxis or chemokinesis, checkerboard 
analysis was performed and showed that both stimuli in a 
dose dependent manner induced HLMC migration when 
added to the lower wells of the chemotaxis chamber. An 
optimal concentration of the stimuli added with the cells 
to the upper wells or to both compartments did not induce 
directional HLMC migration. Thus, DFP-uPA and 
uPAR84-95-induced migration of HLMC resulted from 
chemotaxis, rather than from chemokinesis (data not 
shown).  
In addition, experiments with different 
concentration of ATF (aa 1–143) (10-9-10-8 M), which 
consists only of the uPAR-binding region of uPA and is 
devoid of enzymatic activity [18], demonstrated that this 
peptide retained its chemotactic properties (Fig. 3D).  
Taken together, these results indicated that uPA induced 
MCs migration by binding uPAR and stimulating its 
interaction with FPRs, most probably through the 
exposure of the uPAR84-95 epitope; indeed, the enzymatic 
activity of uPA was not primarily responsible for inducing 
HLMC chemotaxis.  
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Figure 3. uPAR expression and function in primary 
HLMC cells. 
A:  cytofluorometric analysis of uPAR expression on HLMC cell 
surface. HLMC were incubated with anti-IgE PE monoclonal 
antibody, anti-uPAR polyclonal antibody, isotype-matched 
control polyclonal antibody and FITC-conjugated goat anti-
rabbit antibody. 
B: effect of DFP-uPA on HLMC cell chemotaxis. HLMC were 
allowed to migrate in response to cell medium alone (white 
column), or with the indicated concentrations of RANTES (grey 
column) or DFP-uPA (light grey column) for 3 h at 37°C in a 
humidified (5% CO2) incubator. Values are the mean ± SEM of 
three experiments. *p: <0.05. 
C: effect of uPAR84-95 on HLMC cell chemotaxis. HLMC were 
allowed to migrate in response to cell medium alone (white 
column), or with the indicated concentrations of SCF (grey 
column) or uPAR84-95 (light grey column) for 3 h at 37°C in a 
humidified (5% CO2) incubator. Values are the mean ± SEM of 
three experiments. * p: <0.05. 
D: effect of ATF-uPA on HLMC cell chemotaxis. HLMC were 
allowed to migrate in response to cell medium alone (white 
column), or with the indicated concentrations of RANTES (grey 
column) or ATF-uPA (light grey column) for 3 h at 37°C in a 
humidified (5% CO2) incubator. Values are the mean ± SEM of 
three experiments. * p:  <0.05. 
 
 
IV.  DISCUSSION 
 
A straight relation between cancer and flogosis 
has been extensively described, starting from the 
consideration that inflammatory cells are localized all 
around tumors [9, 34-36].  
The interaction between cancer cells and their 
microenvironment are multiple and can result in both 
progression and arrest of tumor growth [37]. However 
tumor microenvironment is constituted not only by cells 
of the innate and adaptive immune system but also from 
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stromal cells [38]. It has been described that stromal cells, 
from different tumors, are able to synthetize mRNA for 
diverse molecules, for example collagenase, matrix 
metalloproteases and proteases, such as plasmin, all 
responsible of the early stages of tumor growth through 
the degradation of the extracellular matrix components 
(ECM) that is one of the mechanisms that neoplastic cells 
use to invade the interstitial tissue [39].  
Furthermore stromal cells, by producing 
chemoattractant molecules, recruit inflammatory cells into 
tumor sites, influencing them in a way that ultimately 
promotes cancer progression and prognosis [38,40,41]. In 
these context the detection of MCs within the tumor 
argues for their role in the modulation of neoplasia 
biology and hypothize a possible cross-talk with stromal 
cells localized within the tumor [27].  
The three N-formyl receptors named FPR1, FPR2 
and FPR3 are innate immune receptors belonging to the 
pattern recognition receptors and associated to G-proteins. 
Beside their involvement in inflammatory disorders FPRs 
have been described as regulating receptors involved in 
wound healing [42], angiogenesis [25], and myofibroblast 
activation occurring in the context of fibrotic disorders 
[24]. The involvement of FPRs in tumors has been studied 
by few authors and in some animal models where their 
role seems to differ in relation of the ligands or of the 
affected tissue [25]. We have recently showed that FPRs, 
as previously demonstrated in epithelial cells, could be 
involved in the pathogenesis of SSc, an autoimmune 
disease, through different mechanisms, including the 
interaction with the uPA-uPAR system [24]. In this paper 
we describe for the first time the expression of all the 
three FPRs in the human mast cell line HMC-1 (Fig. 1). 
The uPA-uPAR system is an important and 
complex cellular recognition system that mediates 
different activities such as fibrinolysis, cell adhesion and 
migration, and tissue remodeling. In particular uPA, 
uPAR and the plasminogen activator inhibitor type-1 
(PAI-1) are not only strongly upregulated in a wide 
variety of cancer types but their biological levels correlate 
with a poor neoplastic outcome and a more rapid tumor 
progression [22,43]. Nielsen and colleague described 
through in situ hybridization and immunohistochemical 
studies of invasive ductal breast cancer tissue that uPA, 
uPAR and PAI-1 are expressed in stromal cells 
immediately surrounding the invasive cancer cells [44].  
We therefore studied the expression, at mRNA 
and protein levels, of uPA and uPAR in HMC-1 cells. 
HMC-1 cells, differently from basophils, synthetized uPA 
and expressed uPAR both in the intact and in a cleaved 
form (DII-DIII-uPAR), which is able to bind FPRs 
through the SRSRY sequence (residues 88-92) (Fig. 1). 
Interestingly, uPA itself can cleave uPAR in the DI-DII 
linker region, thus exposing the SRSRYsequence. 
Moreover, by cytofluorimetric analysis using 
HLMC isolated from donors undergoing thoracotomy and 
lung resection, we confirmed that uPAR was expressed on 
the cell surface of the vast majority of HLMC (80-94%). 
We also found that enzymatically inactive uPA (DFP-
uPA) and ATF, which is devoid of enzymatic activity, 
were potent chemoattractants for HLMC as well as the 
uPAR-derived peptide uPAR84–95, containing the SRSRY 
sequence (Fig. 3). Thus, uPA released by MCs can act in 
an autocrine fashion both by cleaving uPAR and exposing 
the SRSRY sequence than, similarly to what happens in 
basophils, by triggering uPAR conformational changes 
able to mediate binding to FPRs and the transmission of 
signals from the cell surface to the inner domains involved 
in MCs chemotaxis.  
We have previously demonstrated that the H. 
pylori-derived peptide Hp(2-20) stimulated eosinophil 
migration through the engagement of FPR2 and FPR3, 
and also induced production of VEGF-A and TGF-beta, 
two key mediators of tissue remodeling [32]. Thus, we 
evaluated the possibility that FPRs stimulation through 
uPA and uPAR84-95 triggering was able to induce synthesis 
and release of the Vascular endothelial growth factor-A 
(VEGF-A). VEGF-A is the most potent proangiogenic 
mediator known so far, involved in endothelial 
proliferation, migration, and survival. It also acts as a 
proinflammatory cytokine [45]. Both DFP-uPA and the 
uPAR84-95 peptide proved to be potent stimuli for VEGF-A 
synthesis and release. It has been demonstrated that, in 
murine models of glioma and meningioma, uPAR and 
cathepsin B knock-out inhibited angiogenesis by 
disrupting the JAK/STAT pathway-dependent VEGF 
expression [46,47]. Thus, uPAR could represent a useful 
target to inhibit VEGF-A mediated angiogenesis both in 
neoplastic and inflammatory diseases [48].  
 
 
V.  CONCLUSION 
 
Our work suggests the possibility that MCs, 
through the expression of the uPA/uPAR system and its 
interaction with FPRs, can be responsible of chronic 
inflammation, tumor progression and angiogenesis. 
Moreover, it can be hypothesized that stromal cells, by 
secreting chemotactic factors, can additionally contribute 
to the recruitment of MCs, for example, in the tumor 
surroundings.  
Finally, the results described in this study may 
have practical implications in inflammatory and neoplastic 
disorders where MCs infiltration play a prominent role. In 
fact, several author recently suggested that the crosstalk 
between MCs and other tumor-infiltrating cells could be a 
potential target for anticancer therapies [13], or it is 
conceivable that agents acting on uPAR-mediated 
chemotaxis (i.e., by blocking the chemotactic epitope) 
may be used to modify the MCs driven inflammatory and 
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